Trial recruiting people with T1 diabetes and nephropathy

This investigator-initiated trial tests the effect of the oral first-in-class NADH oxidase (Nox)-1/4 inhibitor on albuminuria, and is based on impressive effects in animals shown by Professors Mark Cooper and Karin Jandelheit-Dahm in Melbourne. We are looking for people with type 1 diabetes and persistently abnormal urine albumin to creatinine ratio despite treatment with ACE inhibitor or ARB. These adults aged 18-70 years will have HbA1c < 10% and eGFR ≥60 ml/min/1.73 m2. The treatment period is for 48 weeks, with total study duration for the participant of up to 56 weeks. There will be 10 study visits. The study team is headed by Professor Jonathan Shaw and is funded by the Juvenile Diabetes Research Fund (JDRF) Australia, the recipient of the Australian Research Council Special Research Initiative in Type 1 Juvenile Diabetes. The site investigators are located in multiple states. If you have any potentially suitable patients or would like more information, please contact

If you are interested in displaying information on these pages you must email Carolyn on with the following information:


  • Your full name and contact details
  • The name of Member Centre and member code (if known)
  • A brief summary of the trial you wish to advertise including:
  • Who is heading up the study?
  • Where funding is coming from?
  • Type of participants required and how many.
  • Details of who to contact if interested in the study.
  • Opening and closing dates of the trail.
  • Any other organisations are involved